Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of innovative therapies targeting hematologic disorders and cancer. Its primary function is to advance medicines that address unmet medical needs in immunology and oncology, with a notable focus on rare blood disorders and malignancies. The company's product portfolio includes Tavalisse, an oral spleen tyrosine kinase inhibitor indicated for adult patients with chronic immune thrombocytopenia, and Rezlidhia, a treatment for relapsed or refractory acute myeloid leukemia with specific genetic mutations. Rigel’s research-driven approach leverages expertise in signaling pathways to develop targeted therapies aimed at improving patient outcomes. With a robust pipeline and active commercial operations, Rigel Pharmaceuticals plays a significant role among mid-sized biotech firms, contributing to advancements in precision medicine and offering new options for conditions with limited existing treatments. The company’s operations have an impact across healthcare sectors, particularly in hematology and oncology, reinforcing its significance in biopharmaceutical innovation and patient care within the broader pharmaceutical market.